

CADTH COMMON DRUG REVIEW

Clinical Review Report (Sample)

GENERIC DRUG NAME (BRAND NAME)

(Manufacturer)

Indication: Text

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Table of Contents

| | |
|--|----|
| Abbreviations | 4 |
| Executive Summary | 5 |
| Introduction..... | 5 |
| Results and Interpretation | 5 |
| Introduction | 6 |
| Disease Prevalence and Incidence | 6 |
| Standards of Therapy | 6 |
| Drug..... | 6 |
| Objectives and Methods..... | 7 |
| Objectives..... | 7 |
| Methods..... | 7 |
| Results | 8 |
| Findings from the Literature..... | 8 |
| Included Studies | 9 |
| Exposure to study treatments..... | 10 |
| Critical Appraisal | 10 |
| Efficacy..... | 10 |
| Harms..... | 10 |
| Discussion..... | 11 |
| Summary of Available Evidence | 11 |
| Interpretation of Results | 11 |
| Conclusions | 11 |
| Appendix 1: Patient Input Summary | 12 |
| Appendix 2: Literature Search Strategy | 13 |
| Appendix 3: Excluded Studies | 14 |
| Appendix 4: Detailed Outcome Data | 15 |
| Appendix 5: Validity Of Outcome Measures | 16 |
| Appendix 6: Summary of Other Studies | 17 |
| Appendix 7: Summary Of Indirect Comparisons..... | 18 |

Abbreviations

| | |
|------------------------|--|
| Drug | |
| Indication | |
| Listing Request | |
| Manufacturer | |

Executive Summary

Introduction

Results and Interpretation

Included Studies

Efficacy

Harms

Other Considerations

Conclusions

Introduction

Disease Prevalence and Incidence

Standards of Therapy

Drug

Objectives and Methods

Objectives

Methods

Table 1: Inclusion criteria for the systematic review

| | |
|---------------------------|--|
| Patient Population | |
| Intervention | |
| Comparators | |
| Outcomes | |
| Study Design | |

Results

Findings from the Literature

Figure 1: Flow Diagram for Inclusion and Exclusion of Studies




Table 2: Details of Included Studies

| | | Study Name | Study Name |
|----------------------------------|---------------------------|------------|------------|
| DESIGNS & POPULATIONS | Study Design | | |
| | Locations | | |
| | Randomized (N) | | |
| | Inclusion Criteria | | |
| | Exclusion Criteria | | |
| DRUGS | Intervention | | |
| | Comparator(s) | | |
| DURATION | Phase | | |
| | Run-in | | |
| | Double-blind | | |
| | Follow-up | | |
| OUTCOMES | Primary End Point | | |
| | Other End Points | | |
| NOTES | Publications | | |

Included Studies

Description of studies

Populations

Inclusion and exclusion criteria

Baseline characteristics

Interventions

Outcomes

Statistical analysis

Analysis populations

Patient Disposition

Exposure to study treatments

Critical Appraisal

Internal validity

External validity

Efficacy

Key efficacy outcome 1

Key efficacy outcome 2

Other efficacy outcomes

Harms

Adverse events

Serious adverse events

Withdrawals due to adverse events

Mortality

Notable harms

Discussion

Summary of Available Evidence

Interpretation of Results

Efficacy

Harms

Other Considerations

Potential Place in Therapy¹

Conclusions

¹ This information is based on information provided in draft form by the clinical expert consulted by CDR reviewers for the purpose of this review.

Appendix 1: Patient Input Summary

Appendix 2: Literature Search Strategy

Appendix 3: Excluded Studies

| Reference | Reason for Exclusion |
|-----------|----------------------|
| | |
| | |
| | |

Appendix 4: Detailed Outcome Data

Appendix 5: Validity Of Outcome Measures

Appendix 6: Summary of Other Studies

Appendix 7: Summary Of Indirect Comparisons

References